Nov 02, 2017
New Data of Emicizumab Presented
at The American Society of Hematology 2017
TOKYO, November 2, 2017 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that oral and poster presentations will be given with regard to emicizumab at The American Society of Hematology (ASH) 2017 in Atlanta, Georgia, United States. Emicizumab is a bispecific antibody under development for hemophilia A.
Data from additional six-month follow-up of global Phase lll studies in hemophilia A with inhibitors to factor VIII, HAVEN 1 study (NCT02622321) and HAVEN 2 study (NCT02795767), will be shown at the conference. The HAVEN 2 will be presented at 7:30 EST on December 9 as part of the official Press Program at ASH. Both studies have been conducted in collaboration with Roche and Genentech, while HAVEN 1 is for adults and adolescents and HAVEN 2 is for children.
In addition, preliminary data from HAVEN 4 study (NCT03020160), a Phase lll study with hemophilia A patients with or without inhibitors which examines emicizumab prophylaxis administered subcutaneously once every four weeks, and real-world data from a non-interventional trial in children under 12 years of ages with hemophilia A with inhibitors will be presented.
Major abstracts regarding emicizumab at ASH 2017
Abstract title | Abstract number/Presentation details |
Emicizumab Prophylaxis in Adolescent/Adult Patients with Hemophilia A Previously Receiving Episodic or Prophylactic Bypassing Agent Treatment: Updated Analyses from the HAVEN 1 Study | #1071 Poster (session 322) 09 Dec 2017 17:30 – 19:30 EST |
HAVEN 2 Updated Analysis: Multicenter, Open-label, Phase 3 Study to Evaluate Efficacy, Safety and Pharmacokinetics of Subcutaneous Administration of Emicizumab Prophylaxis in Pediatric Patients with Hemophilia A with Inhibitors | #85 Oral presentation (session 322) 09 Dec 2017 09:45 EST (09:30 – 11:00 EST) |
Emicizumab Subcutaneous Dosing Every 4 Weeks for the Management of Hemophilia A: Preliminary Data from the Pharmacokinetic Run-in Cohort of a Multicenter, Open-label, Phase 3 Study (HAVEN 4) | #86 Oral presentation (session 322) 09 Dec 2017 10:00 EST (09:30 – 11:00 EST) |
Bleeding Events and Safety Outcomes in Pediatric Persons with Hemophilia A with Inhibitors: The First Non-interventional Study (NIS) from a Real-World Setting | #1089 Poster (session 322) 09 Dec 2017 17:30 – 19:30 EST |
Contact:
- For Media
- Chugai Pharmaceutical Co., Ltd.
- Media Relations Group, Corporate Communications Dept.,
- Koki Harada
- Tel: +81-3-3273-0881
- E-mail: pr@chugai-pharm.co.jp
- For Investors
- Chugai Pharmaceutical Co., Ltd.
- Investor Relations Group, Corporate Communications Dept.,
- Toshiya Sasai
- Tel: +81-3-3273-0554
- E-mail: ir@chugai-pharm.co.jp